Pono Capital Two, Inc.

The post-de-SPAC entity is demonstrating accelerating profitability and revenue growth following 2025 restructuring, with 287 clinic locations and management citing AI-enabled service enhancements driving fee increases expected to add ~$15M annually.

This is a governance deficiency rather than a price or filing failure, and the cure is straightforward — appoint a qualified independent director — but the clock is real and the audit committee cannot function with fewer than three independent members under the heightened standards. For former PTWO holders the risk is not immediate delisting but the loss of a functioning audit committee during the gap, which affects the credibility of the financial reporting it oversees.

The meeting straddles the date line and the proxy states both sides of it, so any calendar storing one date without its timezone shows the meeting on the wrong day for half its readers. The record date is the close of business Eastern Time on May 20, 2026. The charter amendments are put as several separate proposals rather than one, letting holders accept some and reject others. The board recommends FOR all nominees, FOR the auditor and FOR each charter proposal, and materials are furnished primarily over the internet.

Four amendments to the merger agreement across roughly ten months, from October 2023 through April 2024, signal a deal repeatedly renegotiated rather than a clean path to closing, and each amendment typically shifts terms toward the target. The Nasdaq proposal authorises up to 100 million new shares, an issuance so large relative to a small SPAC share base that public holders who do not redeem will be reduced to a minority stub. Trust redemption remains the only way to exit at the deposited value before that dilution takes effect.

The share count is not fixed: the $1,000,000,000 of value is delivered solely in new Pono shares, each valued at the price per share at which Pono Class A common stock is redeemed or converted in the redemption required by its charter and IPO prospectus. The number of shares SBC receives is therefore only determined once the redemption price is known. The meeting date, time, webcast address and even the post-closing Nasdaq ticker symbols are left blank in this preliminary version, so nothing here fixes a deadline.

What changed: SBC Medical Group Holdings (formerly PTWO) filed its 10-Q for Q2 2026, reporting $184.3M cash, $92.2M revenue (up 1.7% YoY for six months), and $22.0M net income attributable to the company. The VIE (AMM) was deconsolidated on June 10, 2026, after the CEO/controlling shareholder repaid $5.2M owed by AMM, resulting in a $3.6M deemed contribution. Why it matters: This is a routine post-deal quarterly report for a closed SPAC, with no redemption deadlines, trust value, or extension matters at issue. The deconsolidation of the VIE and the CEO's subrogation payment are notable but do not materially affect the company's financial position or SPAC-related investor considerations.

What changed: SBC Medical reported Q2 2026 revenue of $49M (+13% YoY) and net income attributable to SBC Medical of $11M (+335% YoY), with Adjusted EBITDA of $20M (+32% YoY). The company holds $184M in cash and cash equivalents as of June 30, 2026. Why it matters: The post-de-SPAC entity is demonstrating accelerating profitability and revenue growth following 2025 restructuring, with 287 clinic locations and management citing AI-enabled service enhancements driving fee increases expected to add ~$15M annually.

What changed: SBC Medical Group Holdings, the Pono Capital Two successor, told Nasdaq on July 8, 2026 that as of that day's annual meeting it would cease to comply with the independent director and audit committee requirements of Listing Rule 5605, because Mike Sayama did not seek re-election. On July 10, 2026 Nasdaq confirmed the breach and granted a cure period under Rules 5605(b)(1)(A) and 5605(c)(4) to the earlier of the next annual meeting or July 9, 2027, or to January 5, 2027 if that meeting comes first. A majority-independent board and a three-member independent audit committee are required. Why it matters: This is a governance deficiency rather than a price or filing failure, and the cure is straightforward — appoint a qualified independent director — but the clock is real and the audit committee cannot function with fewer than three independent members under the heightened standards. For former PTWO holders the risk is not immediate delisting but the loss of a functioning audit committee during the gap, which affects the credibility of the financial reporting it oversees.